Discover more insights into Cytogenetic Risk 細胞遺伝学的リスク

Keywords frequently search together with Cytogenetic Risk 細胞遺伝学的リスク

Narrow sentence examples with built-in keyword filters

Cytogenetic Risk sentence examples within Intermediate Cytogenetic Risk



Gene expression profiling in normal cytogenetic acute myeloid leukaemia of Malay patient


Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML)

Cytogenetic Risk sentence examples within Adverse Cytogenetic Risk



Dysregulation of CCAAT/enhancer binding protein-alpha (CEBPA) expression in the bone marrow of acute myeloid leukemia patients


Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia.

Cytogenetic Risk sentence examples within Poor Cytogenetic Risk



Clinical implication and prognostic significance of FLT3-ITD and ASXL1 mutations in Egyptian AML patients: A singlecenter study.


Allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome in adolescent and young adult patients


Learn more from Cytogenetic Risk 細胞遺伝学的リスク


Cytogenetic Risk sentence examples within High Cytogenetic Risk



Targeting UCHL1 Induces Cell Cycle Arrest in High-Risk Multiple Myeloma with t(4;14)


Treatment patterns and outcomes in real-world transplant-ineligible patients newly diagnosed with multiple myeloma

Cytogenetic Risk sentence examples within Assign Cytogenetic Risk



Pre-transplant bone marrow monocytic myeloid-derived suppressor cell frequency is not associated with outcome after allogeneic hematopoietic cell transplantation for acute myeloid leukemia in remission


Relationship between CD33 expression, splicing polymorphism, and in vitro cytotoxicity of gemtuzumab ozogamicin and the CD33/CD3 BiTE® AMG 330

Cytogenetic Risk sentence examples within Standard Cytogenetic Risk



Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life Survey


Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Russian Multicenter Clinical Trial

Cytogenetic Risk sentence examples within cytogenetic risk group



Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial


Disseminated intravascular coagulopathy in non-promyelocytic acute myeloid leukemia: Incidence, clinical and laboratory features and prognostic significance

Cytogenetic Risk sentence examples within cytogenetic risk category



Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes


A parsimonious 3-gene signature predicts clinical outcomes in an acute myeloid leukemia multicohort study.

Cytogenetic Risk sentence examples within cytogenetic risk stratification



MYC protein expression does not correlate with MYC abnormalities detected by FISH but predicts an unfavorable prognosis in de novo acute myeloid leukemia.


Risk Factors for Early Relapse after Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome

Cytogenetic Risk sentence examples within cytogenetic risk classification



Development of a Nomogram for Predicting the Cumulative Incidence of Disease Recurrence of AML After Allo-HSCT


Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma.

Cytogenetic Risk sentence examples within cytogenetic risk statu



De novo isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive cases


Melphalan Dose Intensity for Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma

Cytogenetic Risk sentence examples within cytogenetic risk factor



Autologous and Allogeneic Hematopoietic Cell Transplantation for Diffuse Large B-cell Lymphoma-Type Richter Syndrome.


Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia

Cytogenetic Risk sentence examples within cytogenetic risk profile



Molecular and cytogenetic characteristics of myeloid malignancies following luminal gastrointestinal cancer.


The VR-DCEP regimen rescues mobilization failures and controls refractory disease in multiple myeloma

Cytogenetic Risk sentence examples within cytogenetic risk patient



CKS1-dependent proteostatic regulation has dual roles combating acute myeloid leukemia whilst protecting normal hematopoiesis


Clinical implication and prognostic significance of FLT3-ITD and ASXL1 mutations in Egyptian AML patients: A singlecenter study.


Genetic Identification of AML Patients Older than 60 years Achieving Long-term Survival with Intensive Chemotherapy.



Alpha-Particle Exposure Induces Mainly Unstable Complex Chromosome Aberrations which do not Contribute to Radiation-Associated Cytogenetic Risk.



Analysis of the effectiveness of multiple myeloma treatment based on the clinical experience of European countries



Splenectomy for haemophagocytic lymphohistiocytosis of unknown origin: risks and benefits in 21 patients



Development of a poor-prognostic-mutations derived immune prognostic model for acute myeloid leukemia



The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center.



MRD assessment using NGS in patients with acute myeloid leukemia undergoing hematopoietic stem cell transplantation: Meta-analysis.



Editorial: Special Issue on Innovative Multi-Disciplinary Approaches for Precision Studies in Leukemia



Personalized prediction of overall survival in patients with AML in non‐complete remission undergoing allo‐HCT



Subgroup analysis of ICARIA‐MM study in relapsed/refractory multiple myeloma patients with high‐risk cytogenetics



4CPS-287 Impact of SARS-CoV-2 infection in acute myeloid leukaemia patients: experience of the Pethema registry



Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy.



Impact of stratifying levels of serum lactate dehydrogenase (LDH) at diagnosis on the overall survival (OS) in newly diagnosed multiple myeloma (NDMM).



Subcutaneous daratumumab (DARA SC) plus lenalidomide versus lenalidomide alone as maintenance therapy in patients (pts) with newly diagnosed multiple myeloma (NDMM) who are minimal residual disease (MRD) positive after frontline autologous stem cell transplant (ASCT): The phase 3 AURIGA study.



Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk



On Behalf of the SFGM-TC: Retrospective Comparison of Reduced and Higher Intensity Conditioning for High-Risk Myelodysplastic Syndrome Treated With Allogeneic Stem-Cell Transplantation.



The Prognostic Value of Early Detection of Minimal Residual Disease as Defined by Flow Cytometry and Gene Mutation Clearance for Myelodysplastic Syndrome Patients After Myeloablative Allogeneic Hematopoietic Stem-Cell Transplantation



Prognostic factors of overall (OS) and relapse-free survival (RFS) for patients with acute myeloid leukemia (AML) in remission after intensive chemotherapy (IC): Multivariate analyses from the QUAZAR AML-001 trial of oral azacitidine (Oral-AZA).



Real-world renal function among patients with multiple myeloma in the United States



Comparison of haploidentical and umbilical cord blood transplantation after myeloablative conditioning.



Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy.



MM-431: A Comparison Between Daratumumab and Non-Daratumumab-Based Salvage Regimens Used at First Relapse Post-Lenalidomide Maintenance in Multiple Myeloma



Post remission consolidation by autologous HCT for AML in CR1, negative implications for subsequent allogeneic HCT in CR2. A Study by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).



Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observational Study



Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma



Do Cytogenetics Predict Likelihood to Attain Minimal Residual Disease (MRD) Post Autologous Stem Cell Transplantation (SCT) in Multiple Myeloma (MM)



The evolving role of maintenance therapy following autologous stem cell transplantation in multiple myeloma



[Clinical characteristics of young multiple myeloma patients: a single-center analysis of 30 patients].



A minimális residualis betegség vizsgálatának jelentősége myeloma multiplex kezelése után



Impact of Obesity on Clinical Outcomes of Elderly Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies.



Increased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1.



Acute Myeloid Leukemia in Mexico: The Specific Challenges of a Developing Country. Results From a Multicenter National Registry.


Cytogenetic Risk 細胞遺伝学的リスクの概要


Cytogenetic Risk 細胞遺伝学的リスク
Encyclopedia 百科事典